Latest News

Learn the 10 weekly dashboard metrics Kathleen Moe, MD, tracks to spot issues early, boost access, cash flow, and patient experience in her practice.

Lynk Pharmaceuticals has dosed the first patient in a phase 2 trial evaluating investigational topical pan-JAK inhibitor LNK01004 for vitiligo.

A JAMA Dermatology study suggests higher cumulative isotretinoin doses, not higher daily doses, may help reduce acne relapse.

FDA clears SkinStylus microneedling for under-eye wrinkles in all skin types, expanding uses for acne and abdominal scars amid booming aesthetics demand.

The FDA accepted Arcutis' supplemental NDA seeking to expand roflumilast cream 0.05% to infants aged 3 months to younger than 2 years with mild to moderate AD.

This review of the latest dermatological studies includes insights on granulomatous dermatoses during dupilumab therapy, SAAD-41 validation in alopecia, updated vitiligo trends, and more.

A 30-day trial finds multi-step, barrier-friendly skin care routine cuts acne lesions, oil and redness while boosting hydration in acne-prone skin.

A recent JAAD study identified a dual Th17/Type 2 immune signature in psoriasis that may help explain why biologic responses vary among patients.

Teva will advance TEV-'408 into phase 2b after encouraging phase 1b vitiligo data showed repigmentation, favorable safety, and quarterly dosing potential.

Turn Therapeutics finalized its stage 2 trial design after interim data showed clinically meaningful GX-03 efficacy in patients with baseline EASI scores as low as 1.1.

At a recent Dermatology Times Evolving Paradigms event, Nikhil Khushalani, MD, led dermatologists, Mohs surgeons, and oncologists in comparing systemic immunotherapy selection, referral practices, and adverse event management in advanced cutaneous squamous cell carcinoma.

Can-Fite completed interim enrollment for its pivotal phase 3 trial of first-in-class oral A3AR agonist piclidenoson, a potential new mechanism for plaque psoriasis.

Explore top dermatology conferences and meetings in July 2026 and let us know which ones you'll be attending!